Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Johan W Mouton

Showing results (11-20 of 232) with videos related to

Pageof 24
Sort By:
Clinical Pharmacokinetics|January 20, 2005
Pharmacokinetic/pharmacodynamic modelling of antibacterials in vitro and in vivo using bacterial growth and kill kinetics: the minimum inhibitory concentration versus stationary concentrationJohan W Mouton, Alexander A Vinks
Antimicrobial Agents and Chemotherapy|March 29, 2005
Molecular detection of the macrolide efflux gene: to discriminate or not to discriminate between mef(A) and mef(E)Corné H W Klaassen, Johan W Mouton
Expert Review of Anti-Infective Therapy|December 10, 2014
Isavuconazole, a broad-spectrum triazole for the treatment of systemic fungal diseasesSeyedmojtaba Seyedmousavi, Paul E Verweij, Johan W Mouton
Antimicrobial Agents and Chemotherapy|June 20, 2007
Concentration-effect relationship of ceftazidime explains why the time above the MIC is 40 percent for a static effect in vivoJohan W Mouton, Nieko Punt, Alexander A Vinks
The Journal of Antimicrobial Chemotherapy|November 30, 2012
Optimal exposures of ceftazidime predict the probability of microbiological and clinical outcome in the treatment of nosocomial pneumoniaAnouk E Muller, Nieko Punt, Johan W Mouton
Clinical Therapeutics|August 25, 2005
A retrospective analysis using Monte Carlo simulation to evaluate recommended ceftazidime dosing regimens in healthy volunteers, patients with cystic fibrosis, and patients in the intensive care unitJohan W Mouton, Nieko Punt, Alexander A Vinks
The Journal of Antimicrobial Chemotherapy|August 24, 2018
Variation of MIC measurements: the contribution of strain and laboratory variability to measurement precisionJohan W Mouton, Joseph Meletiadis, Andreas Voss, et al.
Antimicrobial Agents and Chemotherapy|April 10, 2019
<i>In Vitro</i> and <i>In Vivo</i> Exposure-Effect Relationship of Liposomal Amphotericin B against Aspergillus fumigatusMaria Siopi, Johan W Mouton, Spyros Pournaras, et al.
The Journal of Antimicrobial Chemotherapy|April 17, 2019
Variation of MIC measurements: the contribution of strain and laboratory variability to measurement precision-authors' responseJohan W Mouton, Joseph Meletiadis, Andreas Voss, et al.
European Journal of Obstetrics, Gynecology, and Reproductive Biology|October 17, 2002
The epidemiology of vaginal colonisation with group B streptococci in a sexually transmitted disease clinicErik Honig, Johan W Mouton, Willem I van der Meijden
Pageof 24

Showing results (11-20 of 232) with videos related to

Sort By:
Pageof 24
Clinical Pharmacokinetics|January 20, 2005
Pharmacokinetic/pharmacodynamic modelling of antibacterials in vitro and in vivo using bacterial growth and kill kinetics: the minimum inhibitory concentration versus stationary concentrationJohan W Mouton, Alexander A Vinks
Antimicrobial Agents and Chemotherapy|March 29, 2005
Molecular detection of the macrolide efflux gene: to discriminate or not to discriminate between mef(A) and mef(E)Corné H W Klaassen, Johan W Mouton
Expert Review of Anti-Infective Therapy|December 10, 2014
Isavuconazole, a broad-spectrum triazole for the treatment of systemic fungal diseasesSeyedmojtaba Seyedmousavi, Paul E Verweij, Johan W Mouton
Antimicrobial Agents and Chemotherapy|June 20, 2007
Concentration-effect relationship of ceftazidime explains why the time above the MIC is 40 percent for a static effect in vivoJohan W Mouton, Nieko Punt, Alexander A Vinks
The Journal of Antimicrobial Chemotherapy|November 30, 2012
Optimal exposures of ceftazidime predict the probability of microbiological and clinical outcome in the treatment of nosocomial pneumoniaAnouk E Muller, Nieko Punt, Johan W Mouton
Clinical Therapeutics|August 25, 2005
A retrospective analysis using Monte Carlo simulation to evaluate recommended ceftazidime dosing regimens in healthy volunteers, patients with cystic fibrosis, and patients in the intensive care unitJohan W Mouton, Nieko Punt, Alexander A Vinks
The Journal of Antimicrobial Chemotherapy|August 24, 2018
Variation of MIC measurements: the contribution of strain and laboratory variability to measurement precisionJohan W Mouton, Joseph Meletiadis, Andreas Voss, et al.
Antimicrobial Agents and Chemotherapy|April 10, 2019
<i>In Vitro</i> and <i>In Vivo</i> Exposure-Effect Relationship of Liposomal Amphotericin B against Aspergillus fumigatusMaria Siopi, Johan W Mouton, Spyros Pournaras, et al.
The Journal of Antimicrobial Chemotherapy|April 17, 2019
Variation of MIC measurements: the contribution of strain and laboratory variability to measurement precision-authors' responseJohan W Mouton, Joseph Meletiadis, Andreas Voss, et al.
European Journal of Obstetrics, Gynecology, and Reproductive Biology|October 17, 2002
The epidemiology of vaginal colonisation with group B streptococci in a sexually transmitted disease clinicErik Honig, Johan W Mouton, Willem I van der Meijden
Pageof 24